Univariate analysis of risk factors of vascular complications in 69 female patients with essential thrombocythemia and clonal or polyclonal XCIPs
| Features . | Occurrence of thrombosis . | Occurrence of hemorrhage . | ||||
|---|---|---|---|---|---|---|
| Yes, n = 25 . | No, n = 44 . | P . | Yes, n = 16 . | No, n = 53 . | P . | |
| Age, y* | 66.4 ± 16.2 | 48.5 ± 18.5 | <.001 | 70.1 ± 10.2 | 50.4 ± 19.5 | <.001 |
| 40 or younger† | 1 | 15 | — | 0 | 16 | — |
| 41 to 55† | 5 | 12 | — | 0 | 17 | — |
| 56 to 65† | 6 | 8 | — | 6 | 8 | — |
| 66 to 75† | 5 | 5 | — | 5 | 5 | — |
| 76 or older | 8 | 4 | — | 5 | 7 | — |
| Hematocrit, %*,† | 37.3 ± 4.5 | 35.8 ± 5.3 | .245 | 35.7 ± 6.3 | 36.6 ± 4.6 | .531 |
| WBC count, × 109/L* | 16.3 ± 7.5 | 14.1 ± 8.4 | .272 | 19.7 ± 11.4 | 13.5 ± 6.4 | .010 |
| Less than or equal to 12† | 7 | 21 | — | 3 | 25 | — |
| Greater than 12† | 18 | 23 | — | 13 | 28 | — |
| Platelet count, × 109/L* | 1226.4 ± 395.9 | 1311.0 ± 402.4 | .402 | 1208.2 ± 369.3 | 1302.1 ± 408.7 | .414 |
| Less than or equal to 1200† | 16 | 21 | — | 10 | 27 | — |
| Greater than 1200† | 9 | 23 | — | 6 | 26 | — |
| Follow-up, mo* | 50.0 ± 33.6 | 53.3 ± 34.4 | .701 | 50.3 ± 32.4 | 52.7 ± 34.6 | .801 |
| Clonal XCIP† | 24 | 30 | .007 | 14 | 40 | .492 |
| Elevated LAP score† | 21 | 28 | .073 | 14 | 35 | .124 |
| Splenomegaly† | 9 | 7 | .057 | 6 | 10 | .175 |
| Myelofibrosis† | 8 | 20 | .274 | 7 | 21 | .768 |
| Hypertension† | 10 | 4 | .002 | 5 | 9 | .287 |
| Diabetes mellitus† | 3 | 3 | .463 | 2 | 4 | .617 |
| Hypercholesterolemia† | 4 | 4 | .448 | 3 | 5 | .376 |
| Features . | Occurrence of thrombosis . | Occurrence of hemorrhage . | ||||
|---|---|---|---|---|---|---|
| Yes, n = 25 . | No, n = 44 . | P . | Yes, n = 16 . | No, n = 53 . | P . | |
| Age, y* | 66.4 ± 16.2 | 48.5 ± 18.5 | <.001 | 70.1 ± 10.2 | 50.4 ± 19.5 | <.001 |
| 40 or younger† | 1 | 15 | — | 0 | 16 | — |
| 41 to 55† | 5 | 12 | — | 0 | 17 | — |
| 56 to 65† | 6 | 8 | — | 6 | 8 | — |
| 66 to 75† | 5 | 5 | — | 5 | 5 | — |
| 76 or older | 8 | 4 | — | 5 | 7 | — |
| Hematocrit, %*,† | 37.3 ± 4.5 | 35.8 ± 5.3 | .245 | 35.7 ± 6.3 | 36.6 ± 4.6 | .531 |
| WBC count, × 109/L* | 16.3 ± 7.5 | 14.1 ± 8.4 | .272 | 19.7 ± 11.4 | 13.5 ± 6.4 | .010 |
| Less than or equal to 12† | 7 | 21 | — | 3 | 25 | — |
| Greater than 12† | 18 | 23 | — | 13 | 28 | — |
| Platelet count, × 109/L* | 1226.4 ± 395.9 | 1311.0 ± 402.4 | .402 | 1208.2 ± 369.3 | 1302.1 ± 408.7 | .414 |
| Less than or equal to 1200† | 16 | 21 | — | 10 | 27 | — |
| Greater than 1200† | 9 | 23 | — | 6 | 26 | — |
| Follow-up, mo* | 50.0 ± 33.6 | 53.3 ± 34.4 | .701 | 50.3 ± 32.4 | 52.7 ± 34.6 | .801 |
| Clonal XCIP† | 24 | 30 | .007 | 14 | 40 | .492 |
| Elevated LAP score† | 21 | 28 | .073 | 14 | 35 | .124 |
| Splenomegaly† | 9 | 7 | .057 | 6 | 10 | .175 |
| Myelofibrosis† | 8 | 20 | .274 | 7 | 21 | .768 |
| Hypertension† | 10 | 4 | .002 | 5 | 9 | .287 |
| Diabetes mellitus† | 3 | 3 | .463 | 2 | 4 | .617 |
| Hypercholesterolemia† | 4 | 4 | .448 | 3 | 5 | .376 |